2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2480 Comparison of acute graft versus host disease phenotype following post-transplant cyclophosphamide versus calcineurin inhibitor-based GVHD prophylaxis

Pranay Sunil Hegde, MD, Suneeta Godbole, PhD2, Sally Arai, MD3, Sushma Bharadwaj, MD4, Saurabh Dahiya, MD5, Mathew J. Frank, MD, PhD6, Laura Johnston, MD7, Vanessa E Kennedy, MD8, Robert Lowsky, MD9, Everett Meyer, MD, PhD10, Lekha Mikkilineni, MD, MA11, Robert Negrin, MD12, Andrew Rezvani, MD13, Parveen Shiraz, MD14, Judith Anne Shizuru, MD, PhD15, Surbhi Sidana, MD16, Melody Smith, MD,MS17, Hyma Vempaty18, Wen-Kai Weng, MD, PhD19, David Miklos, MD, PhD20, Lori Muffly, MD21, Hany Elmariah, MD,MS22
1 Stanford University, Stanford, California, United States
2 Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States
8 Stanford University, Stanford, California, United States
9 Stanford University, Stanford, California, United States
10 Stanford University, Stanford, California, United States
11 Stanford University, Stanford, California, United States
12 Stanford University, Stanford, California, United States
13 Stanford University, Stanford, California, United States
14 Stanford University, Stanford, California, United States
15 Stanford University, Stanford, California, United States
16 Stanford University, Stanford, California, United States
17 Stanford University, Stanford, California, United States
18 Stanford University, Stanford, California, United States
19 Stanford University, Stanford, California, United States
20 Stanford University, Stanford, California, United States
21 Stanford University, Stanford, California, United States
22 Stanford University, Stanford, California, United States

Background: Acute graft versus host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (alloHCT). Post-transplant cyclophosphamide (PtCy) has emerged as a new standard prophylaxis platform, yielding superior GVHD-free, relapse-free survival compared to tacrolimus/methotrexate (Tac/MTX). While prior studies have established clear reductions in GVHD incidence, PtCy's impact on the clinical presentation of aGVHD is not well studied. 

Methods: This single-center retrospective study included all adult patients who underwent first alloHCT with either PtCy or Tac/MTX at Stanford University between January 1, 2016 and December 31, 2025, and developed aGVHD. The primary objective was to compare aGVHD-related death between regimens, and secondarily compare phenotypic differences in aGVHD including severity, organ distribution, and response to therapy. The primary endpoint was incidence of aGVHD-related death within 1 year after transplant, defined as non-relapse mortality (NRM) with active aGVHD. Rates were compared with competing risks of relapse or other NRM using Fisher’s exact test. Multivariable analysis was performed using Lasso regression to select covariates included in the final models: donor source, recipient age, and Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) for NRM, adding donor age, donor-recipient ABO matching, and Karnofsky Performance Status (KPS) for OS.  

Results: A total of 365 patients (n=131 PtCy, n=234 Tac/MTX) met inclusion criteria for this study with median follow-up time 30.5 months from transplant. Patients receiving PtCy were older (median 63 years vs. 60 years Tac/MTX, p=0.01), while donors were of similar age (median 34 years vs. 35 years, p=0.6). Both groups had mostly non-Hispanic, White patients (54% PTCy and 60% Tac/MTX), and had comparable pre-transplant KPS and HCT-CI scores. PtCy patients were more likely to receive reduced-intensity conditioning regimens (79% vs 52% Tac/MTX, p<0.001), and a plurality of patients were transplanted for acute myeloid leukemia (50% PtCy and 35% Tac/MTX, p=0.058). Patients receiving PtCy were less likely to have a matched donor (37.4% vs 93.6% Tac/MTX, p<0.001). The primary outcome, aGVHD-related death at 1 year, was lower in the PtCy group (3.1% vs 12% Tac/MTX, p=0.01). Similarly, NRM was lower (4.6% vs 18%, p<0.001), and overall survival (OS) at 1-year was higher (88% vs 76%, p=0.016). In multivariable analysis, NRM in the PtCy group remained superior (sHR 0.25, 95% CI 0.12-0.53, p<0.001) as did OS (HR 0.37, 95% CI 0.21-0.64, p<0.001).  

Median time to aGVHD onset was shorter in the PtCy group (44 days vs 33 days Tac/MTX, p<0.001). The aGVHD distribution by grade was 57% grade 1, 37% grade 2, 3.8% grade 3, and 2.3% grade 4 in the PtCy group compared to 38% grade 1, 38% grade 2, 18% grade 3, and 5.1% grade 4 in the Tac/MTX group. By organ, rates of skin involvement (88% PtCy vs 83% Tac/MTX, p=0.3) and liver involvement (3.1% PtCy vs 0.8% Tac/MTX, p=0.13) were similar between groups. Upper GI (14% PtCy vs 24% Tac/MTX, p=0.016) and lower GI (8.4% PtCy vs 35% Tac/MTX, p<0.001) involvement were lower in the PtCy group.  Complete response (CR) rates to systemic steroids for aGVHD grades 2-4 were 43% in the PtCy group and 20% in the Tac/MTX group (p<0.001). Median time to first CR to aGVHD therapy was 19 days in the PtCy group and 25 days in the Tac/MTX group (p<0.001), with 24% in the PtCy and 27% in the Tac/MTX groups developing steroid-dependent aGVHD (p=0.7). In the PTCy group, 13% developed steroid-refractory aGVHD, compared to 29% of Tac/MTX patients (p<0.001). In total, 19% of patients in the PtCy group were admitted for aGVHD-related complications compared to 41% in the Tac/MTX group (p< 0.001). Among those admitted, median days of hospitalization were similar between groups (22 days PtCy vs 32 days Tac/MTX, p=0.3). Progression to chronic GVHD was observed in 10% of PtCy patients and 15% of Tac/MTX patients (p=0.3). 

Conclusions: In a cohort of patients who developed aGVHD after alloHCT, prophylaxis with PtCy was associated with decreased risk of aGVHD-related death and higher OS at 1-year post-transplant compared to Tac/MTX. Patients receiving PtCy had longer time to aGVHD onset, higher steroid responsiveness by grade, and decreased upper and lower GI involvement. These results suggest aGVHD developing after PtCy is less severe and more treatment responsive when compared to Tac/MTX. 

Pranay Sunil Hegde, MD: No relevant conflicts of interest to declare.